Compass Therapeutics presents preclinical data on CTX-10726

Compass Therapeutics (CMPX) announced its poster presentation at the 40th Society for Immunotherapy of Cancer, SITC, Annual Meeting, taking place November 5-9, 2025, in National Harbor, MD. Data highlights from the poster presentation include: In vitro, CTX-10726: Showed high-affinity binding to both human and cynomolgus monkey VEGF-A and PD-1; Effectively blocked VEGF-A/VEGFR2 and PD-1/PD-L1 interactions in a dose-dependent manner; and Demonstrated potent immunomodulatory activity as measured by IFN-gamma production. In vivo, CTX-10726: Exhibited superior anti-tumor efficacy in a human lung cancer model in mice compared to ivonescimab and an anti-VEGF-A antibody; Showed stronger anti-tumor activity against a human-PD-L1 expressing colon cancer cell line implanted in human PD-1/PD-L1 double knock-in mice, compared with ivonescimab; and Demonstrated anti-tumor activity against human-PD-1 and VEGF-A expressing colon cancer cell line implanted in human PD-1/PD-L1/VEGF-A triple knock-in mice, with significant reduction in tumor size compared with bevacizumab.